Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022GlobeNewsWire • 03/01/22
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022GlobeNewsWire • 02/24/22
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTIGlobeNewsWire • 02/02/22
Evoke Pharma's (EVOK) CEO Dave Gonyer on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/11/21
Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021GlobeNewsWire • 11/03/21
Evoke Pharma's Commercial Partner EVERSANA, Receives PM360's Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTIGlobeNewsWire • 09/29/21
Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/01/21
Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders' (IFFGD) August Gastroparesis Awareness MonthGlobeNewsWire • 08/02/21
Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD's Industry CouncilGlobeNewsWire • 06/29/21
Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research StudyGlobeNewsWire • 06/15/21
Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal SprayGlobeNewsWire • 05/27/21
Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/13/21
Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®GlobeNewsWire • 04/06/21